5AM Ventures
Venture capitalBoston · Seed–Late Stage · 45 people tracked
Also known as 5AM VENTURE MANAGEMENT, LLC
Investment thesis
5AM Ventures backs life science and biotech companies, concentrating on biopharmaceuticals, drug delivery technologies, and life science instruments. Its main strategy invests in private, early-stage therapeutic companies with an emphasis on Series A financings, while an Opportunities strategy targets small and mid-cap public and later-stage private biotech and life science companies. Through its internal '4:59' effort, the firm takes a hands-on approach to discovering, incubating, and funding breakthrough science, partnering with academics and entrepreneurs and often acting as an extension of the operating team to generate proof-of-concept data that supports a Series A round.
Source: firm website, verified Aug 3, 2026.
Team · 45 people
from the firm's website & public directories
What they invest in
from 36 of 102 portfolio companiesBiotech ×32Healthtech ×9Medical Devices ×7AI & Machine Learning ×4Digital Health ×4Deep Tech ×3Enterprise Software ×1Media & Entertainment ×1
HQs:United States×39
Investments · 102 tracked
founders shown can be your intro pathSan Diego, US
Board seatBrian Daniels· per SEC Form D · $120M raise · filed Apr 2021
BiotechRadnor, US
Mark Simon(Director)Steven Nichtberger(Executive Officer, Director)Dan Geffken(Executive Officer)
Board seatBrian Daniels· per SEC Form D
BiotechCambridge, US
RICHARD YOUNG(Director)MICHAEL HIGGINS(Director)JORGE CONDE(Director)JOSH MANDEL-BREHM(Executive Officer, Director)
BoardAMIR NASHAT(Director)
Board seatAndrew J. SchwabAndy Schwab· per SEC Form D · filed Jun 2022
Entrada Therapeutics develops intracellular therapeutics using its EEV Platform to target previously inaccessible disease-causing targets within cells, with a pipeline spanning retinal, neuromuscular, and metabolic diseases including Duchenne muscular dystrophy.
BiotechHealthtechMedical DevicesBoston, US
Carole Nuechterlein(Director)Natarajan Sethuraman(Executive Officer)Kush M. Parmar(Director)inTodd Foley(Director)Peter Kim(Director)Nerissa Kreher(Executive Officer)
Board seatKush M Parmar· per SEC Form D · $116.2M raise · filed Apr 2021
Ideaya Biosciences develops precision medicines and targeted therapies for patients with hard-to-treat cancers and high unmet need.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)Yujiro Hata(Executive Officer, Director)Timothy Shannon(Director)Terry Rosen(Director)Jeffrey Stein(Director)John Diekman(Director)
Board seatJohn DiekmanBrian Daniels· per SEC Form D
BiotechFramingham, US
Anand Varadan(Director)Richard Batycky(Director)Michael Higgins(Director)Peter Ludlum(Interim CEO; Interim CFO)Christopher Cabell(Director)Todd Bazemore(Director)
Board seatScott Rocklage· per SEC Form D
New Haven, US
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D · $6.6M raise · filed Apr 2024
Bedford, US
Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018
San Diego, US
Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.
BiotechHealthtechMedfield, US
Jamil Beg(Director of the Issuer)Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Kevin Bitterman(Director of the Issuer)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.
BiotechDeep TechSouth San Francisco, US
BiotechCambridge, US
Alexander M. Seaver(Manager of the Issuer)G. Houston Hall(Manager of the Issuer)Adrian Z. Stecyk(Manager of the Issuer)Mark J. Pykett(Manager of the Issuer)Arthur Tzianabos(Manager of the Issuer)
Board seatArthur Tzianabos· per SEC Form D · $5M raise · filed Feb 2016
BiotechBrookline, US
Emmanuel Simons(Executive Officer, Director)Ed Mathers(Director)Kush Parmar(Director)
Board seatKush M ParmarArthur Tzianabos· per SEC Form D
La Jolla, US
Peppi Presit(Director)Richa Nand(Executive Officer)Bradley Bolzon(Director)Ray Stevens(Director)Simon Nebel(Director)Simeon George(Director)
Board seatAndrew J. Schwab· per SEC Form D
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Steve Elms(Director)Dan Burgess(Director)Scott Rocklage(Director)Ted Schroeder(Director)Kevin Forrest(Executive Officer)
Board seatScott Rocklage· per SEC Form D · $20.2M raise · filed Oct 2017
Boston, US
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D · $129M raise · filed May 2023
BiotechBurlingame, US
Robert Schreiber(Director)John Celebi(Executive Officer)John Diekman(Director)Mark Goldsmith(Director)Carl Gordon(Director)David Goeddel(Director)
Board seatJohn Diekman· per SEC Form D · $6.3M raise · filed Jan 2015
South San Francisco, US
Geoffrey Richardson(Executive Officer)Dipender Saluja(Director)Sam Bergh(Director)Suk-Bae Cha(Director)Bruce Sohn(Director)Scott Rocklage(Director)
Board seatScott Rocklage· per SEC Form D · $54.6M raise · filed Jun 2018
BiotechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)Jim Tananbaum(Director)Kevin Raidy(Director)
Board seatDeborah Palestrant· per SEC Form D · $150M raise · filed Feb 2025
Pioneering the development of prescription digital therapeutics.
HealthtechBoston, US
Antoun Nabhan(Executive Officer)Corey McCann(Executive Officer, Director)Andrew Schwab(Director)Timothy Petersen(Director)Christopher Guiffre(Executive Officer)
BoardZack Lynch(Director)
Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016
BiotechVancouver
Andrew Booth(Director)Andrew J. Schwab(Director)R. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Euan Ramsay(Executive Officer)Daniel Nixon(Director)
Board seatAndrew J. Schwab· per SEC Form D · $13.4M raise · filed Nov 2016
BiotechLexington, US
Kurt Graves(Director)Steven Gillis(Director)Robert Connelly(Director)Michael Higgins(Director)David Edwards(Director)Terrance McGuire(Director)
Board seatScott Rocklage· per SEC Form D · $34.1M raise · filed Jun 2015
BiotechPleasanton, US
Barney E. Saunders,Ph.D.(Chief Executive Officer)Steve Reichenbach(Chief Financial Officer)Bill W. Colston, Ph.D.(Director)Mira Chaurushiya, Ph.D.(Director)Kevin Corcoran(Director)Klint Rose, Ph.D.(Chief Scientific Officer)
Board seatJoseph J. Victor· per SEC Form D · $34.4M raise · filed Apr 2021
Seattle, US
Robert Shepler(Director)Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Brian Daniels(Director)Joseph Victor(Executive Officer, Director)Frank Witney(Director)
Board seatAndrew Schwab· per SEC Form D
Santa Clara, US
John Borkholder(Executive Officer)Samuel Colella(Director)Vince Murphy(Executive Officer)Scott Rocklage(Director)Todd Werpy(Director)Robert Wedinger(Executive Officer, Director)
Board seatScott Rocklage· per SEC Form D
Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.
AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US
Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)
BiotechWaltham, US
Kenneth Evan Thompson(Executive Officer)Jonathan Violin(Executive Officer, Director)Leon Moulder(Director)
BiotechSan Diego, US
JeenJoo Kang(Director)Robert Tjian(Director)Alain Baron(Executive Officer, Director)Marcus Boehm(Executive Officer)Andrew Schwab(Director)
BiotechDel Mar, US
Paul Stone(Executive Officer)Yujiro Hata(Director)Kevin Forrest(Executive Officer, Director)Scott Rocklage(Executive Officer, Director)Matthew Disney(Director)Jason Hafler(Director)
Preclinical biotech developing extracellular protein degraders for autoimmune disease using CustomGlycan platform.
Hayward, US
BiotechBedford, US
Steven Gillis(Director)Siyamak Rasty(Executive Officer)Richard Gregory(Director)Kush Parmar(Director)Albert Seymour(Executive Officer)
BoardArthur Tzianabos(Executive Officer, Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does 5AM Ventures invest at?
- 5AM Ventures invests at the Seed, Series A, Growth, Late Stage stages.
- What is 5AM Ventures's typical check size?
- 5AM Ventures typically writes checks of $100K – $4M.
- What sectors does 5AM Ventures focus on?
- 5AM Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is 5AM Ventures located?
- 5AM Ventures is headquartered in Boston, US.
- Does 5AM Ventures lead rounds?
- Yes, 5AM Ventures leads investment rounds.
Co-investors · 40
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
OUP (Osage University Partners) is a venture capital firm that backs science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
▶28 more co-investors
venBio PartnersThe Column GroupArboretum VenturesForesite CapitalLongwood FundWestlake Village BioPartnersTelegraph Hill PartnersNew Enterprise Associates (NEA)EQT Life SciencesSR One Capital ManagementAndera PartnersNextech InvestConnecticut InnovationsIllumina VenturesKleiner PerkinsVenrockVersant VenturesForbionDeerfield Management CompanyAbingworthFrazier Healthcare PartnersHatteras Venture PartnersNew Leaf Venture PartnersAlta PartnersHealthQuest CapitalJMI EquityAltitude Ventures Management, LlcHive Ventures
Firms observed investing alongside 5AM Ventures, from public investor directories. Shared companies are the overlap with 5AM Ventures's recorded portfolio.
Similar investors
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.